FindTrial
Sign In

Impact of Shock Wave Therapy on male sexual impotence

Impact of Low-Intensity Extracorporeal Shock Wave Therapy in the treatment of erectile dysfunction

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-6wnxv2
Enrollment
Unknown
Registered
2017-04-18
Start date
2017-04-10
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erectile Dysfunction, coronary artery disease.

Interventions

Procedure/surgery
E02.565.280.945
60 patients will be randomly enrolled into two groups: Experimental group - 30 men with heart disease and sexual impotence, using phosphodiesterase type 5 inhibitors, will receive applications of Lo
The impulses will be applied in the distal, middle and proximal portions of the penile shaft, bilaterally, and in the right and left crura. The application session will be weekly, lasting 20 minutes a
Device

Sponsors

Faculdade de Medicina do ABC
Lead Sponsor
Faculdade de Medicina do ABC
Collaborator

Eligibility

Sex/Gender
Male
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Older than 18 years; confirmed and non-disabling coronary artery disease; erectile dysfunction for more than 6 months classified as mild to moderate (IIEF> 15); erectile dysfunction responsive to use 5PDEi; exclusive sexual partner; preserved libido.

Exclusion criteria

Exclusion criteria: Patients with uncontrolled diabetes mellitus (Glycated Hemoglobin> 10%); low testosterone levels; previous radical prostatectomy or other pelvic surgeries; patients with structural abnormalities of the penis; pelvic radiation history; central and peripheral neuropathies; psychiatric disorders; using anticoagulants

Design outcomes

Primary

MeasureTime frame
Obtain an average of at least 5 points higher in the IIEF-5 of experimental group after 1 week of the application of shock wave therapy.;Obtain an average of at least 5 points higher in the IIEF-5 of experimental group after 12 weeks of the application of shock wave therapy.—

Secondary

MeasureTime frame
To evaluate the percentage of patients who discontinued the use of inhibitors of phosphodiesterase type 5 in the experimental group and compare it to that of the control group.;Obtain an average of at least 3 points higher in the IIEF-5 of experimental group after 12 weeks of the application of shock wave therapy. ;To evaluate and compare the incidence of adverse effects in both groups.—

Countries

Brazil

Contacts

Public ContactCristiano Pazeto

Faculdade de Medicina do ABC

cristianolinckpazet@gmail.com+55-11-49935400

Outcome results

None listed

Source: REBEC (via WHO ICTRP)